1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsApplications reviewed on a rolling basis throughout the year; notifications sent within 4-6 weeks of submission.
Innovation Grants Program is sponsored by Infiltrate Bio. Infiltrate Bio provides funding opportunities for tumor infiltration and related research areas through their adhesion biomarker platform. This is highly relevant to immunotherapy development and optimization.
Get alerted about grants like this
Save a search for “Infiltrate Bio” or related topics and get emailed when new opportunities appear.
Search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Innovation Grants Program | Infiltrate Bio Innovation Grants Program Ready to advance your research? Apply for our Innovation Grants Program and gain access to cutting-edge tumor infiltration prediction that could accelerate your cell therapy development process.
Advancing Immune Therapy Research This grant is open to researchers, academic institutions, biotech companies, and pharmaceutical partners looking to integrate cutting-edge tumor infiltration prediction technology into their work. Applicants should have a strong scientific rationale and a clear plan for utilizing Infiltrate Bio's adhesion biomarker platform. Applications are reviewed on a rolling basis throughout the year.
Submit a 250-word proposal outlining your project objectives, research plan, and relevance to immune infiltration. Review cycles occur on a rolling basis with notifications sent within 4-6 weeks of submission. Our Innovation Grants support pilot studies analyzing primary T cells, CAR-T cells, PBMCs, or other immune cell populations.
Infiltration biomarker analysis service with our adhesion chromatography platform Up to 20 immune cell samples per pilot study Comprehensive analysis report with infiltration predictions, adhesion metrics, and expert interpretation Consultation on experimental design, data analysis, and results interpretation All samples must be submitted to Infiltrate Bio within 3 months of grant acceptance Accepted Sample Types (choose one category per application) Primary T cells: CD4+, CD8+, or mixed T cell populations Engineered cells: CAR-T, TCR-T, or other genetically modified immune cells PBMCs: Peripheral blood mononuclear cells or other immune cell preparations Open to researchers affiliated with academic institutions, biotechnology companies, or pharmaceutical organizations Grant recipients are expected to share results through publication, conference presentation, or poster presentation at a relevant scientific conference within 12 months of grant acceptance Applications are accepted on a rolling basis.
Start your research innovation today. Research Area * Select research area Industry * Select industry Sample Type * Select sample type I agree to the Terms and Conditions of the Innovation Grants Program * Terms and Conditions Apply.
Key questions and narrative sections extracted from the solicitation.
First Name, Last Name, Email Address, Organization, Job Title
Research Area (select from dropdown)
Industry (select from dropdown)
Sample Type (choose one: Primary T cells, Engineered cells such as CAR-T or TCR-T, or PBMCs)
Project Description: 250-word proposal outlining project objectives, research plan, and relevance to immune infiltration
Based on current listing details, eligibility includes: Researchers, academic institutions, biotech companies, and pharmaceutical partners looking to integrate cutting-edge tumor infiltration prediction technology into their work. Applicants should have a strong scientific rationale and a clear plan for utilizing Infiltrate Bio's adhesion biomarker platform. Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates Service access (infiltration biomarker analysis) Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is rolling deadlines or periodic funding windows. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
Federal grant success rates typically range from 10-30%, varying by agency and program. Build a strong proposal with clear objectives, measurable outcomes, and a well-justified budget to improve your chances.
Requirements vary by sponsor, but typically include a project narrative, budget justification, organizational capability statement, and key personnel CVs. Check the official notice for the complete list of required attachments.
Yes — AI tools like Granted can help research funders, draft proposal sections, and check compliance. However, always review and customize AI-generated content to reflect your organization's unique strengths and the specific requirements of the solicitation.
Review timelines vary by funder. Federal agencies typically take 3-6 months from submission to award notification. Foundation grants may be faster, often 1-3 months. Check the program's timeline in the official solicitation for specific dates.
Many federal programs offer multi-year funding or allow competitive renewals. Check the official solicitation for continuation and renewal policies. Non-competing continuation applications are common for multi-year awards.
Past winners and funding trends for this program
-Purpose. This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to develop, standardize, and validate new and innovative assays, integrated strategies, or batteries of assays that determine or predict specific organ toxicities (e.g., ocular, dermal, hematotoxicity, cardiotoxicity, gastrointestinal toxicity, hepatotoxicity, nephrotoxicity, ototoxicity, olfactory loss, bladder toxicity, neurotoxicity, pulmonary toxicity, endocrine toxicity, and pancreatic beta cell toxicity), resulting from both acute and chronic exposures to various chemicals, environmental pollutants, biologics and therapeutic molecules or drugs. In addition, this FOA encourages the development, standardization, and validation of new models of arthritis, convulsion, infection and shock. New approaches for high throughput toxicity screening that involves the use of molecular endpoints, computer modeling, proteomics, genomics and epigenomics and the development of virtual tissues are also encouraged as are development of 3-dimensional organ models for toxicity evaluation. -Mechanism of Support. This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I, Phase II, and Fast-Track applications and runs in parallel with a FOA of identical scientific scope, PA-09-007, which encourages applications under the Small Business Technology Transfer (STTR) (R41/R42) grant mechanisms. Funding Opportunity Number: PA-09-006. Assistance Listing: 93.113,93.173,93.361,93.389,93.837,93.846,93.847,93.848,93.849,93.859,93.867. Funding Instrument: G. Category: ED,ENV,FN,HL.
Purpose. This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), National Institutes of Health (NIH), invites Small Business Innovation Research (SBIR) cooperative agreement applications from small business concerns (SBCs) that propose to develop new, or to improve existing application(s) of nanotechnology-based therapeutics or/and in vivo diagnostics. This FOA will specifically support pre-clinical optimization and testing of these cancer-relevant nanotechnology applications against the intended cancer type. The proposed projects must be milestone-driven and must be clearly directed toward development of an ultimate commercial product. The outcomes are expected to advance the discovery and pre-clinical optimization phase so that an Investigational New Drug (IND) or Investigational Device Exemptions (IDE) application could be submitted to the Food and Drug Administration (FDA) by the end or shortly after completion of the Phase II project period. To facilitate these steps, the NCI will assist the awardees in various ways, including the support through the NCI-sponsored Nanotechnology Characterization Laboratory. This FOA will NOT support basic research projects, studies on disease mechanisms, and clinical trials. Mechanism of Support. This FOA will utilize the SBIR (U43/U44) cooperative agreement mechanisms for Phase I and Phase II applications. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received. Funding Opportunity Number: PAR-10-286. Assistance Listing: 93.393,93.394,93.395,93.396. Funding Instrument: CA. Category: ED,HL. Award Amount: Up to $150K per award.